NasdaqGM:KYMRBiotechs
A Look At Kymera Therapeutics (KYMR) Valuation After Positive KT-621 Atopic Dermatitis Data
Kymera Therapeutics (KYMR) drew fresh attention after sharing positive Phase 1b data for KT-621 in moderate to severe atopic dermatitis. The results were highlighted in a late breaking oral session at the American Academy of Dermatology meeting.
See our latest analysis for Kymera Therapeutics.
The fresh KT-621 Phase 1b data came on the back of strong share price momentum, with a 7 day share price return of 9.26% and a 90 day share price return of 17.37%. Over the longer term, the 1 year total...